Sardines, mackerel and other oily fish: The benefits of marine lipids in the fight against cancer
The world's oceans represent a vast and largely untapped source of biodiversity, offering a high probability for the ...
What's Going On With Moleculin Biotech Shares Wednesday?
Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...
Moleculin Evaluates Prelim. Activity Of Annamycin In Acute Ara-C, VEN Resistant Myeloid Leukemia
(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
Daiichi Sankyo doses first subject in Phase III AML therapy trial
Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML
The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...
ENDPOINTS NEWS4d
Ku­ra On­col­o­gy de­tails 'ag­gres­sive' ap­proach in first-line AML
Kura Oncology and Kyowa Kirin reported positive Phase 1 results for oral menin inhibitor ziftomenib in acute myeloid leukemia ...
Oncology Nurse Advisor5d
Approach Produces “Excellent” CRc Rate in Newly Diagnosed AML
The team found that cladribine plus low-dose cytarabine and venetoclax as induction and consolidation, alternating with azacitidine and venetoclax consolidation, produced high rates of composite ...
Kura Oncology, Kyowa Kirin report data on KOMET-007 at ASH meeting
Kura Oncology (KURA) and Kyowa Kirin provided encouraging clinical data from KOMET-007, a Phase 1 dose-escalation trial of ziftomenib, a highly ...
manilatimes5d
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
Kura Oncology, Inc. (Nasdaq: KURA, "Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin”) provided encouraging cli ...